![Chad D. Galderisi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Sheridan G. Snyder | M | - |
MolecularMD Corp.
![]() MolecularMD Corp. Medical/Nursing ServicesHealth Services MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR. | 19 Jahre |
Drew Graham | M | - |
MolecularMD Corp.
![]() MolecularMD Corp. Medical/Nursing ServicesHealth Services MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR. | - |
Matt Rice | M | - |
MolecularMD Corp.
![]() MolecularMD Corp. Medical/Nursing ServicesHealth Services MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Dan Snyder | M | - |
MolecularMD Corp.
![]() MolecularMD Corp. Medical/Nursing ServicesHealth Services MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR. | - |
Stephane Wong | M | - |
MolecularMD Corp.
![]() MolecularMD Corp. Medical/Nursing ServicesHealth Services MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR. | - |
Ryan Dunlap | M | 54 |
MolecularMD Corp.
![]() MolecularMD Corp. Medical/Nursing ServicesHealth Services MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR. | - |
Frederick L. Eibel | M | 60 |
MolecularMD Corp.
![]() MolecularMD Corp. Medical/Nursing ServicesHealth Services MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR. | - |
Brian Druker | M | 68 |
MolecularMD Corp.
![]() MolecularMD Corp. Medical/Nursing ServicesHealth Services MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR. | - |
Courtney Fuller | F | - |
MolecularMD Corp.
![]() MolecularMD Corp. Medical/Nursing ServicesHealth Services MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR. | - |
Glenn J. Dozier | M | 74 |
MolecularMD Corp.
![]() MolecularMD Corp. Medical/Nursing ServicesHealth Services MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR. | - |
Glenn A. Miller | M | - |
MolecularMD Corp.
![]() MolecularMD Corp. Medical/Nursing ServicesHealth Services MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR. | - |
Peter Maag | M | 57 |
MolecularMD Corp.
![]() MolecularMD Corp. Medical/Nursing ServicesHealth Services MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR. | 8 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 12 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Chad D. Galderisi
- Persönliches Netzwerk